{"id":"s-1-oxaliplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hand-foot syndrome"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-1 (tegafur, gimeracil, oteracil potassium) is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase to disrupt DNA synthesis. Oxaliplatin is a third-generation platinum compound that binds DNA and forms interstrand and intrastrand crosslinks, leading to apoptosis. The combination leverages complementary mechanisms of action for enhanced antitumor activity.","oneSentence":"S-1 is a combination of three components that inhibit thymidylate synthase and fluorodeoxyuridine monophosphate formation, while oxaliplatin is a platinum-based agent that forms DNA crosslinks, together providing synergistic cytotoxic effects against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:59.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (advanced or metastatic)"},{"name":"Colorectal cancer (advanced or metastatic)"}]},"trialDetails":[{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07492615","phase":"PHASE2","title":"A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-29","conditions":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":276},{"nctId":"NCT06538623","phase":"PHASE2","title":"Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2024-08-23","conditions":"Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer","enrollment":40},{"nctId":"NCT07483567","phase":"PHASE2","title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-30","conditions":"CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07474324","phase":"PHASE2","title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-15","conditions":"GC/GEJC","enrollment":124},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT07464756","phase":"PHASE2","title":"SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-04-05","conditions":"Gastric Adenocarcinoma","enrollment":80},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT07384234","phase":"PHASE2","title":"SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-31","conditions":"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","enrollment":60},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT06693128","phase":"PHASE2","title":"Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-21","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":80},{"nctId":"NCT07374250","phase":"PHASE2","title":"Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2026-02-01","conditions":"Gastric Cancer, RCT","enrollment":154},{"nctId":"NCT07366528","phase":"PHASE3","title":"Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-15","conditions":"Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer","enrollment":387},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT04208347","phase":"PHASE2, PHASE3","title":"Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-12-18","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":580},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07356466","phase":"EARLY_PHASE1","title":"Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Fujian Medical University","startDate":"2025-05-01","conditions":"Gastric (Stomach) Cancer","enrollment":100},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT07353684","phase":"PHASE2","title":"Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-05-11","conditions":"Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach","enrollment":49},{"nctId":"NCT07325630","phase":"PHASE2","title":"Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-03","conditions":"IBI363 + Chemotherapy","enrollment":60},{"nctId":"NCT07315854","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-11-04","conditions":"Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer","enrollment":32},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT03443492","phase":"PHASE2","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-03-26","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":130},{"nctId":"NCT06576921","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-11-15","conditions":"Stomach Neoplasms, Immune Checkpoint Inhibitors","enrollment":116},{"nctId":"NCT06730009","phase":"PHASE1, PHASE2","title":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","status":"RECRUITING","sponsor":"Medigen Biotechnology Corporation","startDate":"2024-10-21","conditions":"Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable","enrollment":42},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT03013010","phase":"PHASE3","title":"PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Shanghai Cancer Hospital, China","startDate":"2016-12","conditions":"Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma","enrollment":204},{"nctId":"NCT05322577","phase":"PHASE1, PHASE2","title":"A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-05-17","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":72},{"nctId":"NCT07263386","phase":"PHASE2","title":"A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-23","conditions":"Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT07072351","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-15","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy","enrollment":88},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT05177068","phase":"PHASE2","title":"Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2022-05-13","conditions":"Gastric Cancer","enrollment":42},{"nctId":"NCT07194005","phase":"PHASE2","title":"Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-04","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07098949","phase":"NA","title":"Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08","conditions":"Gastric Cancer","enrollment":346},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT06732856","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-04-04","conditions":"Stomach Neoplasm, Gastric (Stomach) Cancer","enrollment":57},{"nctId":"NCT06949033","phase":"PHASE3","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-05-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":668},{"nctId":"NCT07056010","phase":"NA","title":"Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-25","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT07033143","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-07","conditions":"Gastric Cance","enrollment":40},{"nctId":"NCT05161572","phase":"PHASE2","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-09-28","conditions":"Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy","enrollment":6},{"nctId":"NCT07025889","phase":"PHASE1, PHASE2","title":"IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-02","conditions":"Gastric Cancer","enrollment":55},{"nctId":"NCT07026149","phase":"PHASE2","title":"Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-08","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":30},{"nctId":"NCT07018063","phase":"PHASE2","title":"Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"zhoujing","startDate":"2025-10-01","conditions":"Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced","enrollment":35},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT06925243","phase":"PHASE3","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-04-15","conditions":"Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy","enrollment":682},{"nctId":"NCT06939452","phase":"PHASE2","title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","status":"RECRUITING","sponsor":"Yongxu Jia","startDate":"2023-06-07","conditions":"Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","enrollment":37},{"nctId":"NCT06685887","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-15","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT05593458","phase":"PHASE3","title":"Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-04-01","conditions":"Locally Advanced Gastric Carcinoma","enrollment":190},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":"Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","enrollment":140},{"nctId":"NCT05223088","phase":"PHASE2","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-31","conditions":"Immunotherapy, Gastrict Cancer","enrollment":40},{"nctId":"NCT04863430","phase":"PHASE2","title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2021-05-11","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT06405113","phase":"PHASE2","title":"FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhou No.2 People's Hospital","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":198},{"nctId":"NCT04662112","phase":"PHASE1, PHASE2","title":"Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-06-15","conditions":"Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06766578","phase":"PHASE2","title":"Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2024-12-31","conditions":"Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":32},{"nctId":"NCT06157216","phase":"NA","title":"Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Stage II-III Gastric Cancer","enrollment":85},{"nctId":"NCT06760858","phase":"","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":122},{"nctId":"NCT06730373","phase":"PHASE2","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-17","conditions":"HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma","enrollment":110},{"nctId":"NCT03878472","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2019-04-01","conditions":"Gastric Cancer","enrollment":25},{"nctId":"NCT02867839","phase":"PHASE3","title":"Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2017-04-24","conditions":"Gastric Cancer","enrollment":29},{"nctId":"NCT06682182","phase":"","title":"Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer with Peritoneal Metastasis","enrollment":74},{"nctId":"NCT06662877","phase":"PHASE2, PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":"Biliary Tract Cancer, Second Line Treatment, Chemotherapy","enrollment":206},{"nctId":"NCT02969122","phase":"NA","title":"Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor","status":"TERMINATED","sponsor":"Peking University","startDate":"2016-11","conditions":"Stomach Neoplasm","enrollment":59},{"nctId":"NCT05144854","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-05","conditions":"Gastric Cancer","enrollment":626},{"nctId":"NCT06564298","phase":"PHASE2","title":"A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08","conditions":"Stomach Neoplasms","enrollment":39},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT06496789","phase":"PHASE2","title":"Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-27","conditions":"Gastric Adenocarcinoma","enrollment":35},{"nctId":"NCT06475417","phase":"PHASE2","title":"Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-05-24","conditions":"Gastric Cancer","enrollment":42},{"nctId":"NCT06451211","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-17","conditions":"Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach","enrollment":53},{"nctId":"NCT06447636","phase":"PHASE2","title":"Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-08-01","conditions":"Gastric Cancer, Gastro Esophageal Junction Cancer","enrollment":20},{"nctId":"NCT06396585","phase":"PHASE2","title":"The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-08-01","conditions":"Immunotherapy Gastroesophageal Junction","enrollment":28},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT05699655","phase":"PHASE2, PHASE3","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-05-10","conditions":"Immunotherapy Gastrict Cancer","enrollment":130},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT05540145","phase":"","title":"Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-05-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT06341595","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-01","conditions":"Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes","enrollment":40},{"nctId":"NCT05048524","phase":"PHASE2","title":"Peri-operative SLOG for Localized Pancreatic Cancer","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-09-03","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreas Cancer","enrollment":64},{"nctId":"NCT05975749","phase":"PHASE2","title":"Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Gastric Cancer","enrollment":114},{"nctId":"NCT05101616","phase":"PHASE1, PHASE2","title":"A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer","status":"SUSPENDED","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2022-07-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT06284746","phase":"PHASE2","title":"Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Lin Chen","startDate":"2023-10-01","conditions":"Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy","enrollment":80},{"nctId":"NCT05184803","phase":"PHASE2","title":"A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2022-03-23","conditions":"Stomach Neoplasm","enrollment":63},{"nctId":"NCT06266871","phase":"PHASE1, PHASE2","title":"SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-03-10","conditions":"Gastric Cancer","enrollment":64},{"nctId":"NCT06250894","phase":"PHASE2","title":"Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-30","conditions":"PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer","enrollment":32},{"nctId":"NCT04694183","phase":"PHASE2","title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Quan Wang","startDate":"2020-08-17","conditions":"Stomach Neoplasms","enrollment":37},{"nctId":"NCT06238167","phase":"PHASE2","title":"Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-04-01","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06192186","phase":"PHASE4","title":"Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Yang Jianjun, PhD","startDate":"2023-12-30","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":110},{"nctId":"NCT06213519","phase":"PHASE2","title":"HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-02-20","conditions":"Peritoneal Metastases, Gastric Cancer","enrollment":69},{"nctId":"NCT05872685","phase":"PHASE2","title":"Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-12-24","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair","enrollment":314},{"nctId":"NCT06194981","phase":"","title":"Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-01-11","conditions":"Gastric Cancer","enrollment":260},{"nctId":"NCT06202781","phase":"","title":"Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2022-07-01","conditions":"Gastric Cancer, Tumor Microenvironment, Immunotherapy","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":967,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S-1 and Oxaliplatin"],"phase":"phase_3","status":"active","brandName":"S-1 & Oxaliplatin","genericName":"S-1 & Oxaliplatin","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-1 is a combination of three components that inhibit thymidylate synthase and fluorodeoxyuridine monophosphate formation, while oxaliplatin is a platinum-based agent that forms DNA crosslinks, together providing synergistic cytotoxic effects against cancer cells. Used for Gastric cancer (advanced or metastatic), Colorectal cancer (advanced or metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}